Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05754658

African Cancer Genome: GMD

African Cancer Genome Cohort to Promote Health Equity Among Patients of African Ancestry: Characterization of Genetic and Molecular Drivers

Status
Recruiting
Phase
Study type
Observational
Enrollment
1,500 (estimated)
Sponsor
Fox Chase Cancer Center · Academic / Other
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

The goal of this study is to develop a comprehensive characterization of genetic and molecular drivers of breast and prostate cancer in individuals of African ancestry. The study is conducted by the African Caribbean Cancer Consortium (AC3) and involves the recruitment of patients from nine international AC3 research sites in the Bahamas, Barbados, Benin, Burkina Faso, Haiti, Jamaica, Kenya, Namibia, and Trinidad and Tobago, and the US. The main questions are to: molecularly characterize genomic changes in the African Cancer genomes of the breast and prostate and identify the effects of social determinants of health and lifestyle factors on mutational landscape. Black individuals that have been diagnosed with pathologically confirmed prostate or breast cancer will be included. Detailed social determinants of health survey, blood and archived FFPE tissues will be collected. (Tier 1) All patient tissues will be subject to IHC for receptor status (ER, AR, PR Her2/neu). All patients with available germline DNA from blood will receive genetic screening using a Commercial gene panel testing. (Tier 2) Patient samples with a negative genetic screening will be subject to whole exome sequencing or banked for later RNA or methylation sequencing.

Conditions

Interventions

TypeNameDescription
OTHERStandard of CareDrugs routinely administered for breast cancer per local standard.
OTHERStandard of CareDrugs routinely administered for prostate cancer per local standard.

Timeline

Start date
2022-11-28
Primary completion
2025-12-31
Completion
2025-12-31
First posted
2023-03-06
Last updated
2025-10-06

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05754658. Inclusion in this directory is not an endorsement.